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This study demonstrates that
increased expression of (p)
FADD is associated with
a better local control in
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therapy. These findings
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be new prognostic biomarker
to predict local recurrence
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Open access undPurpose: We recently reported on the identification of the Fas-associated death domain (FADD)
as a possible driver of the chromosome 11q13 amplicon and the association between increased
FADD expression and disease-specific survival in advanced-stage laryngeal carcinoma. The aim
of this study was to examine whether expression of FADD and its Ser194-phosphorylated iso-
form (pFADD) predicts local control in patients with early-stage glottic carcinoma primarily
treated with radiotherapy only.
Methods and Materials: Immunohistochemical staining for FADD and pFADD was performed
on pretreatment biopsy specimens of 92 patients with T1eT2 glottic squamous cell carcinoma
primarily treated with radiotherapy between 1996 and 2005. Cox regression analysis was used to
correlate expression levels with local control.
Results: High levels of pFADD were associated with significantly better local control (hazard
ratio, 2.40; 95% confidence interval, 1.04e5.55; p Z 0.040). FADD overexpression showed
a trend toward better local control (hazard ratio, 3.656; 95% confidence interval, 0.853e
15.663; p Z 0.081). Multivariate Cox regression analysis showed that high pFADD expression
was the best predictor of local control after radiotherapy.
Conclusions: This study showed that expression of phosphorylated FADD is a new prognostic
biomarker for better local control after radiotherapy in patients with early-stage glottic carci-
nomas.  2012 Elsevier Inc.
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In squamous cell carcinoma of the head-and-neck region
(HNSCC), DNA amplification of the chromosome 11q13 region is
observed in approximately 30% of all HNSCCs and is therefore
one of the most frequently observed genomic abnormalities (1). In
HNSCC 11q13 amplification is associated with the presence of
lymph node metastases, decreased disease-specific survival, and
decreased overall survival (OS) (2). Recently, we reported that the
commonly amplified 11q13 region in oropharyngeal/laryngeal
carcinomas contains at least 6 genes, FADD (Fas-associated death
domain) (MORT1), PPFIA1 (LIPRIN), ORAOV1 (TAOS1),
FGF19, cortactin (CTTN), and cyclin D1 (CCND1), that are
amplified and overexpressed in almost all carcinomas with 11q13
amplification (3). Of all genes in this 11q13 amplicon, FADD was
not only amplified the most, but overexpression and amplification
of FADD also correlated with increased FADD protein expression,
suggesting that FADD is a key gene in the 11q13 amplicon (3).
Originally, FADD (Fas [TNFRSF6]eassociated via death
domain) was reported as a proapoptotic adaptor molecule that
recruits caspases 8 and 10 to promote formation of the death-
inducing signal complex (4). The recruitment of these caspases to
the death-inducing signal complex leads to intracellular process-
ing and activation of caspases, eventually resulting in cleavage of
downstream targets and apoptosis. More recently, an alternative
function for FADD was described because many studies showed
that FADD also plays an important role in growth and regulation
of the cell cycle (5, 6). Nuclear localization of FADD has been
ascribed to FADD phosphorylation at Ser194 (pFADD), and the
highest levels of pFADD are observed at the G2/M phase of the
cell cycle (7). In addition, treatment of cells in vitro with agents
blocking the G2/M transition resulted in a significant accumula-
tion of pFADD (8, 9). Finally, expression of a Ser194ephospho-
mimicking FADD mutant caused G2/M cell cycle arrest (9).
Altogether, these data suggest a key role for FADD/pFADD in cell
cycle control. Because previous studies showed that cells arrested
in the G2/M phase are most radiosensitive (10), FADD is ampli-
fied in more than 30% of HNSCCs, and pFADD is mainly
expressed at the G2/M phase of the cell cycle, we hypothesize that
glottic carcinomas with overexpression of pFADD will have better
local control (LC) after radiotherapy alone.
In a series of 167 advanced-stage oropharyngeal/laryngeal
carcinomas, we found that increased levels of both FADD and
pFADD were significantly associated with a worse disease-
specific survival and positive lymph node status (3, 11). In
agreement with this finding, in HNSCC, FADD overexpression
and pFADD overexpression in adenocarcinomas of the lung were
both associated with decreased OS (12). In prostate cancer,
pFADD expression was associated with progression of disease (9).
In our series of 167 advanced-stage oropharyngeal/laryngeal
carcinomas, we could not evaluate the prognostic value for
LC after radiotherapy because of the presence of many con-
founding parameters that might influence the clinical outcome,
such as the variety of different (combined) treatment modalities,
different subsites in the head-and-neck region, and differences in
extended disease (e.g., Nþ) and tumor size (3, 11).
In this study we examined the prognostic value of FADD and
pFADD expression in patients with laryngeal carcinoma primarily
treated with radiotherapy alone. To evaluate the effect of FADD/
pFADD expression on clinical outcome after radiotherapy, we
limited the number of possible interfering variables by selectinga homogeneous study population. Of all patients with laryngeal
carcinoma treated at our institution between 1997 and 2004, we
selected 92 patients with early-stage (pT1/pT2) glottic carcinoma
of the larynx who were treated primarily with radiotherapy with
curative intent. Because early-stage glottic carcinomas rarely have
regional lymph node metastasis on initial diagnosis and because
FADD expression has been associated with the presence of lymph
node metastasis in advanced-stage HNSCC as well (11), the
analysis of early-stage glottic cancer will restrict our validation to
LC after radiotherapy. Immunohistochemical staining of FADD
and pFADD on pretreatment biopsy specimens will be correlated
with LC and OS.Methods and Materials
Patients and tissues
The selection of patients and samples was described in detail
previously (13). In brief, between 1997 and 2004, 638 patients
were diagnosed with laryngeal squamous cell carcinoma in the
northern part of the Netherlands (comprising >10 medical
centers) and treated at our institute. Demographic and clinico-
pathologic data, such as sex, age, pretreatment hemoglobin level,
T status, N status, and current and past tobacco use and alcohol
use, were retrospectively collected by reviewing the patient charts.
The inclusion criteria for this study were (1) histologically proven
squamous cell carcinoma, (2) localization in the glottis, (3) cT1
and cT2, (4) no evidence of distant metastasis (cM0), (5) curative
treatment with radiotherapy alone, and (6) no other previous
treatment. From the 360 patients with T1/T2 glottic carcinomas,
157 formalin-fixed, paraffin-embedded pretreatment biopsy spec-
imens were collected and revised by an experienced pathologist.
Tissue specimens with sufficient tumor cells for immunohisto-
chemical staining were available from 92 patients. The pretreat-
ment characteristics are summarized in Table 1. Informed consent
was given by all patients included in the study.
Radiotherapy and follow-up
In all patients radiotherapy was delivered with megavoltage
equipment by use of 6-MV photons as reported previously (13).
T1 tumors were treated with a total dose of 66 Gy at 2 Gy per
fraction, 5 times per week. T2 tumors were generally treated with
6 fractions per week, to a total dose of 70 Gy in 6 weeks. In case
of elective irradiation of the neck nodes, a total dose of 46 Gy was
given on the primary planning target volume with an additional
boost of 70 Gy on the primary tumor and pathologic lymph nodes
(as detailed in the Appendix available online at redjournal.org).
After completing radiation, patients were followed up every
3 months in the first and second year and every 6 months in the
third, fourth, and fifth year. After 5 years without evidence of
disease, patients were discharged from follow-up. Twenty-one
patients in whom a local recurrence developed after radiotherapy
underwent salvage by total laryngectomy; one patient received
palliative therapy because of inoperable recurrent tumor. A second
primary developed in 9 patients (10%), in the lung (nZ 4), head-
and-neck region (n Z 4), or colon (n Z 1). During follow-up,
26 patients (28%), of whom 7 died of disease. All follow-up data
are summarized in Table 2.
Table 1 Patient characteristics: Glottic cancer treated with
primarily radiotherapy
Data (n Z 92) [n (%)]
Sex
Male 82 (89%)
Female 10 (11%)
Age (y)
Median (range) 65 (40e86)
Primary symptom
Hoarse voice 88 (96%)
Other 4 (4%)
T status
1 50 (54%)
2 42 (46%)
N status
0 90 (98%)
1 1 (1%)
X 1 (1%)
Hemoglobin level (mmol/L)
Median 9.1
Past tobacco use (cigarettes per day)
0 4 (4%)
1e20 45 (49%)
>20 20 (22%)
Unknown 23 (25%)
Present tobacco use (cigarettes per day)
0 40 (3%)
1e20 29 (32%)
>20 11 (12%)
Unknown 12 (13%)
Past alcohol use (units per day)
0 25 (27%)
1e6 47 (51%)
>6 3 (3%)
Unknown 17 (18%)
Table 2 Patient characteristics: Follow-up
Characteristics Data (n Z 92) [n (%)]
Events during follow-up
Any 43 (47%)
Local recurrence 22 (24%)
Regional recurrence 3 (3%)
Second primary 9 (10%)
Death 26 (28%)
Death of disease 7 (27%)
Death not of disease 19 (73%)
Time to first event (mo)
Mean 19
Median (range) 13 (0e98)
Time to follow-up (mo)
Mean 49
Median (range) 40 (1e119)
Time to local recurrence (mo)
Mean 14
Median (range) 11.5 (2e46)
Time to regional recurrence (mo)
Mean 11
Median (range) 12 (6e16)
Time to second primary (mo)
Mean 26
Median (range) 10 (0e68)
Time to death (mo)
Mean 33
Median (range) 28 (3e98)
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Immunohistochemical staining and scoring for FADD, pFADD,
cortactin, and cyclin D1 was performed as reported previously
(3, 11) by use of the murine monoclonal antibody A66-2 (BD
Biosciences, Franklin Lakes, NJ), rabbit polyclonal antibody
against Ser194 pFADD (BD Biosciences), murine monoclonal
antibody 30/cortactin (BD Biosciences), and rabbit anti-human
monoclonal antibody SP4 (Lab Vision/Neomarkers, Fremont,
CA), respectively (examples are shown in Fig. E1 available online
at redjournal.org). For the scoring of the immunostaining of
pFADD and cyclin D1, the percentage of tumor cells with nuclear
staining was determined. Cutoff values of percentages for
dichotomization for pFADD were determined by use of receiver
operating curve analyses, and the best sensitivity/specificity ratio
associated with LC was found at a cutoff level of 71%. Percent-
ages of positive staining above the cutoff level were considered as
high expression and those below as negative/low expression.
Scoring was performed by two independent observers without
knowledge of clinical data. The discordant cases were reviewed by
all observers, and scores were reassigned on consensus of opinion.
Detailed information is presented in the Appendix available online
at redjournal.org.Statistical analysis
Associations between expression of FADD, pFADD, cyclin D1,
and cortactin were analyzed with a chi-square test. Follow-up time
was calculated from the date of diagnosis until the date of the last
follow-up visit. Local recurrence was defined as tumor recurrence
at the primary tumor site and was calculated from the date of
diagnosis until the date of local recurrence diagnosis or to the last
follow-up. OS was defined from the date of diagnosis to the date
of death or to last follow-up.
Kaplan-Meier survival analysis and Cox regression analysis
adjusted for expression of FADD and pFADD, as well for sex, age,
hemoglobin level, T status, N status, tobacco use, and alcohol use,
were performed with LC and OS as endpoints. Only variables
showing an association with LC or OS on univariate analysis
(p < 0.10) were included in the multivariate Cox regression
analysis. Alcohol consumption was excluded from the multivar-
iate analysis because of the large number of missing values
(17 missing [18%]). All statistical analyses were performed with
SPSS software, version 16.0 (SPSS, Chicago, IL).
Results
FADD and pFADD are not associated with
clinicopathologic features
Immunohistochemical staining of FADD was mainly cytoplasmic
and very homogeneous across the tumor (Fig. E1A). High levels
of FADD were detected in 21 of 92 cases (23%). The
Table 3 Patient and disease characteristics in total and related to local recurrence after radiotherapy
Characteristics Total Local recurrence [n (%)] Univariate HR (95% CI) p value
FADD expression
Low 71 20 (28%) 3.656 (0.853e15.663) p Z 0.081
High 21 2 (10%) 1
pFADD expression
Low 30 11 (37%) 2.403 (1.041e5.548) p Z 0.040
High 62 11 (18%) 1
Cyclin D1 expression
Low 43 12 (28%) 1.292 (0.558e2.991) p Z 0.550
High 44 10 (23%) 1
Cortactin expression
Low 42 14 (33%) 1.890 (0.762e4.687) p Z 0.169
High 39 7 (18%) 1
Sex
Female 10 1 (10%) 1 p Z 0.323
Male 82 21 (26%) 2.751 (0.370e20.470)
Age
<65 y 46 11 (24%) 1 p Z 0.695
65 y 46 11 (24%) 1.183 (0.511e2.738)
Hemoglobin level
High 70 15 (21%) 1 p Z 0.232
Low 22 7 (32%) 1.731 (0.704e4.257)
T status
T1 50 9 (18%) 1 p Z 0.137
T2 42 13 (31%) 1.906 (0.814e4.463)
N status
N1 1 0 (0%) 1 p Z 0.704
N0 91 22 (24%) 20.570 (0.00e125000000) 10
Current tobacco use
Yes 40 8 (20%) 1 p Z 0.237
No 40 12 (30%) 1.718 (0.701e4.215)
Past tobacco use
No 4 0 (0%) 1 p Z 0.524
Yes 65 16 (25%) 21.941 (0.002e295955)
Alcohol use
No 25 9 (18%) 1 p Z 0.037
Yes 50 13 (31%) 4.816 (1.10e21.087)
Abbreviations: CIZ confidence interval; FADDZ Fas-associated death domain; pFADDZ Ser194-phosphorylated isoform of Fas-associated death
domain; HR Z hazard ratio.
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within the tumor tissues and predominantly found within the
nucleus (Fig. E1B, available online at redjournal.org). High
nuclear pFADD levels were observed in 62 of 92 cases (67%). No
significant association was found between FADD and pFADD
expression (results not shown), which is in agreement with the
different morphologic distributions. No significant associations
were found between FADD or pFADD expression and sex, age,
hemoglobin level, T stage, N stage, current and past tobacco use,
and use of alcohol (data not shown).
Expression of FADD and pFADD predicts increased
LC in early-stage glottic carcinoma
Univariate Cox regression analysis on dichotomized groups
showed that high pFADD expression was associated with better
LC (hazard ratio [HR], 2.40; 95% confidence interval [CI],
1.04e5.55; p Z 0.040), whereas borderline significance for theassociation with this endpoint was found for high FADD expres-
sion (HR 3,66; 95% CI, 0.85e15.66; p Z 0.081) (Table 3).
Kaplan-Meier survival analysis showed similar results for both
pFADD (p Z 0.033) and FADD (pZ 0.060) (Figs. 1A and 1B ).
Interestingly, no local recurrence developed in any of the
12 patients with high expression of both FADD and pFADD,
whereas a local recurrence developed in 22 of the 80 patients with
low expression of either FADD, pFADD, or both (27.5%)
(p Z 0.025) (Fig. 1C). Multivariate Cox regression analysis
showed that high pFADD expression was the strongest indepen-
dent prognostic factor for LC after radiotherapy (HR, 2.72;
95% CI, 1.17e6.29; p Z 0.020) (Table 4).
Expression of FADD or pFADD does not predict
better OS
Kaplan-Meier survival analysis showed that high expression of
FADD (p Z 0.213) and high expression of pFADD (p Z 0.788)
Fig. 1. Local control (LC) rate as a function of (A) Fas-associated death domain (FADD), (B) Ser194-phosphorylated isoform of Fas-
associated death domain (pFADD), and (C) combination of FADD and pFADD. Patients overexpressing FADD show a trend toward better
LC. Patients overexpressing pFADD show significantly better LC. Patients overexpressing both FADD and pFADD have an LC rate
of 100%.
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showed that high expression of FADD (HR, 1.94; 95% CI,
0.67e5.65; pZ 0.223) and high expression of pFADD (HR, 1.12;
95% CI, 0.49e2.55; p Z 0.788) were not associated with OS.
Cyclin D1 and cortactin are not associated with LC
Because cortactin and cyclin D1 are frequently co-amplified and
consequently co-overexpressed with FADD in HNSCC (3, 11) and
have been associated with poor prognosis and/or response to
therapy (3, 14, 15), we immunostained the same series for cor-
tactin and cyclin D1 (examples are shown in Figs. E1C and E1D,
available online at redjournal.org). Increased expression of cyclin
D1 and cortactin was observed in 43 of 92 cases and 39 of 92cases, respectively. Univariate Cox regression analysis (Table 3)
and Kaplan-Meier survival analysis (Fig. E2, available online at
redjournal.org) showed that high expression of cyclin D1 and high
expression of cortactin were not associated with LC in early-stage
glottic cancer.
Discussion
Laryngeal squamous cell carcinoma is the most common type of
HNSCC and accounts for approximately 20% of all newly diag-
nosed HNSCCs. Nowadays, most patients with Stage T1/T2
laryngeal carcinoma are treated with radiotherapy because of
better laryngeal function after treatment compared with surgery.
The 5-year LC and OS rates for T1/T2 laryngeal carcinoma vary
Table 4 Patient characteristics related to local recurrence
after radiotherapy
Characteristics Multivariate HR (95% CI) p value
Low FADD expression 4.227 (0.981e18.320) p Z 0.053
Low pFADD expression 2.715 (1.172e6.287) p Z 0.020
Abbreviations: CI Z confidence interval; FADD Z Fas-associated
death domain; pFADD Z Ser194-phosphorylated isoform of Fas-
associated death domain; HR Z hazard ratio.
Only variables showing a correlation with local control on univariate
analysis (p < 0.10) were included (pFADD and FADD). Alcohol use
was excluded because of the large number of missing values.
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(16). Unfortunately, except for TNM status, no good clinico-
pathologic factors are available to predict clinical outcome in
early-stage laryngeal carcinoma treated with radiotherapy. The
clinical relevance is obvious, because in case of recurrent disease
after radiotherapy, salvage laryngectomy is mandatory, resulting
in loss of vocal cord function and therefore quality of life. Thus
molecular tumor markers could be useful to predict local recur-
rence and survival in patients with early-stage glottic carcinoma
treated with radiotherapy.
Associations between expression of either FADD or pFADD
with clinical outcome have been described in different tumor
types. Chen et al. (12) showed that FADD overexpression and
pFADD overexpression were both associated with decreased OS
in patients with adenocarcinoma of the lung. Shimada et al. (9)
reported that expression of pFADD was associated with
progression of prostate carcinoma. In a previous study we found
an association between FADD and pFADD expression and
clinical outcome in a group of mainly advanced-stage laryngeal
carcinomas (3, 11). No associations could be performed
between FADD/pFADD expression and response to therapy
because of the heterogeneity of the patient series. In this study
we selected a homogeneous series of patients with T1/T2
glottic carcinoma treated with radiotherapy only. Our dataFig. 2. Overall survival (OS) as a function of (A) Fas-associated deat
associated death domain (pFADD). No significant correlation was founshowed that high expression of FADD and, even more signifi-
cantly, pFADD overexpression were associated with better LC.
No association with OS was found. These data strongly suggest
that overexpression of pFADD is associated with better
radiosensitivity.
FADD is part of the chromosome 11q13 amplicon (3). We have
shown that not only FADD but also several other genes in the
amplicon (PPFIA1, TPCN2, FLJ442258, ORAOV1, FGF19,
CTTN/cortactin, CCND1/cyclin D1) are overexpressed in HNSCC
carcinomas with 11q13 amplification (3). Two of these genes
(cyclin D1 and cortactin) have been studied extensively (1).
Cyclin D1 has been associated with response to radiotherapy
previously in breast cancer both in a clinical study (15, 17, 18) and
in an in vitro model (14), and cortactin has been associated with
worse clinical outcome in HNSCC (11) and cell migration in vitro
(19). Immunostaining of the same series of 92 glottic cancers
showed no association between either cortactin or cyclin
D1 expression and LC (Table 3 and Fig. E2). The lack of this
association for cyclin D1 is not consistent with the observed
response to therapy in breast cancer but is concordant with studies
in HNSCC that failed to associate cyclin D1 expression and
clinical outcome (20). In this study we only selected early-stage
(T1/T2) glottic carcinomas, in which the rate of regional or distant
metastasis is relatively low (only 1 of 92), which results from the
less developed lymphatic drainage system of the glottic larynx.
The lack of the observed association between cortactin and LC in
this series of early-stage glottic carcinomas is therefore in good
agreement with cortactin’s function in cell migration and invasion
(19). This analysis showed that not cyclin D1 or cortactin but high
pFADD expression is associated with LC in our series of early-
stage glottic carcinomas.
Our data also suggest that the expression of pFADD might
mediate the sensitivity of tumor cells to radiotherapy. However, at
present, we can only speculate how. Besides the role of FADD in
apoptosis, more recently, phosphorylation of FADD (pFADD) at
serine 194 was reported to be involved in cell cycle progression
(4, 5, 7, 8). Hua et al. (5) showed that phosphorylation of FADD
is essential for growth/proliferation in T cells. Shimada et al. (9)h domain (FADD) and (B) Ser194-phosphorylated isoform of Fas-
d between either FADD or pFADD overexpression and OS.
Schrijvers et al. International Journal of Radiation Oncology  Biology  Physics1226and Alappat et al. (8) have shown that phosphorylation of FADD
caused more cells to be arrested in the G2/M phase of the cell
cycle. A possible explanation for this is that cells in the G2/M
phase are more radiosensitive than cells in other phases of the cell
cycle (10). Furthermore, the fact that phosphorylation of FADD is
associated with nuclear localization in our tumors and is involved
in G2/M arrest in in vitro models (9) suggests that FADD plays an
important role in sensitizing these tumors for radiation. However,
whether pFADD itself triggers cells into G2/M arrest or cells at
G2/M arrest show expression of pFADD has to be tested in future
experiments by knocking down or expressing FADD and pFADD
mutants in HNSCC cell lines and determining RT response
directly by the classical clonogenic survival assay.
Conclusions
We showed that increased expression of pFADD/FADD is
associated with better LC in early-stage glottic carcinoma
treated with radiotherapy alone. A possible explanation is that
pFADD expression is associated with more arrested cells in the
radiosensitive G2/M phase of the cell cycle. Our findings
suggest that pFADD might be a new prognostic biomarker to
predict local recurrence in T1/T2 glottic carcinoma treated with
radiotherapy.
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